The antihypertensive effect of spironolactone in oligo-anuric haemodialysis patients.
Recruiting
- Conditions
- high blood pressurehypertension1003843010057166
- Registration Number
- NL-OMON36327
- Lead Sponsor
- Maasstadziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
-age 18 years and older
-on hemodialysis at least 3 months before inclusion
-daily diuresis less than 500 mL
-predialysis serum potassium < 6 mmol/L
Exclusion Criteria
-myocardial infarction, stroke or transient ischaemic attack less than 6 months before inclusion
-angina pectoris
-heart failure
-hypotension (predialysis systolic blood pressure below 100 mmHg) or severe hypertension (predialysis SBP>180 mmHg and/or DBP>100 mmHg)
-pregnancy
-known allergy to study drugs
-any acute illness requiring treatment
-malignant disease
-expected non-adherence to treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoint is the change in predialysis systolic blood pressure<br /><br>during automatic blood pressure measurement after treatment with spironolactone<br /><br>and triamterene.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints are changes in 24-hours blood pressure, neurohormonal<br /><br>profile, interdialysis weight gain, 24-hours sodium excretion, and serum<br /><br>elektrolyte concentrations.</p><br>